Research on the development of novel renal cancer therapies using histone deacetylase inhibitors and anti-HIV drugs in combination
Project/Area Number |
16H07457
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Urology
|
Research Institution | National Defense Medical College |
Principal Investigator |
ASANO TAKAKO 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究施設、病院並びに防衛, 泌尿器科学, 助教 (40779336)
|
Project Period (FY) |
2016-08-26 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 癌 / シグナル伝達 |
Outline of Final Research Achievements |
It is difficult to induce endoplasmic reticulum (ER) stress by using the histone deacetylase (HDAC) inhibitor alone. On the other hand, the HIV protease inhibitor not only inhibits molecular chaperones and proteasomes but also P-glycoproteins. I postulated that combining an HDAC inhibitor and an HIV protease inhibitor would induce ER stress and histone acetylation effectively. The combination of the HDAC inhibitor entinostat and the HIV protease inhibitor ritonavir induced apoptosis and inhibited renal cancer growth synergistically. As expected, the combination induced ER stress and histone acetylation. In murine subcutaneous tumor models, the combination inhibited tumor growth significantly.
|
Report
(3 results)
Research Products
(3 results)